The National Comprehensive Cancer Network® (NCCN®) has updated the Clinical Practice Guidelines in oncology for breast cancer (Version 1.2019) to include scalp cooling as a Category 2A recommendation to reduce the incidence of chemotherapy-induced alopecia for patients receiving chemotherapy.
“As PAXMAN submitted an application for consideration to the NCCN Breast Cancer Panel last year, we are pleased to announce this major positive step towards a higher quality of life for breast cancer patients undergoing chemotherapy treatment. This recommendation by NCCN is an important step toward increasing patient and provider access to scalp cooling, as the majority of public and private payers recognize NCCN Guidelines® as the gold standard for coverage and reimbursement policies in the US,” says PAXMAN’s CEO Richard Paxman.
“PAXMAN is already the scalp cooling partner of choice for many leading cancer centers in the US, and we are experiencing a strong demand following our expanded FDA clearance last year. Broader payer coverage will help drive greater adoption by US cancer centers and growth in enrolment going forward,” says Richard Paxman.
PAXMAN is experiencing significant growth in the US, both in terms of installed systems and enrolled patients. To date, PAXMAN has around 380 scalp cooling systems installed in the US across 35 states and 233 locations.
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed March 14, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.